Baseline 18F-FDG Metabolic Tumor Volume Predicts Response to Rituximab Induction in Post-transplant Lymphoproliferative Disorders: A Multi-institutional Retrospective Study

Baseline 18F-FDG Metabolic Tumor Volume Predicts Response to Rituximab Induction in Post-transplant Lymphoproliferative Disorders: A Multi-institutional Retrospective Study

Post-transplant lymphoproliferative disorder (PTLD) is a rare complication of immunosuppression. Sequential treatment is commonly proposed, combining induction with rituximab (R-induction) followed by either continuation of treatment or addition of chemotherapy depending on response. Response to R-i...

Full description

Bibliographic Details
Main Authors: David Morland, Lukshe Kanagaratnam, Fabrice Hubelé, Elise Toussaint, Sylvain Choquet, Aurélie Kas, Pierre-Ambroise Caquot, Corinne Haioun, Emmanuel Itti, Stéphane Leprêtre, Pierre Decazes, Fontanet Bijou, Paul Schwartz, Caroline Jacquet, Adrien Chauchet, Julien Matuszak, Nassim Kamar, Pierre Payoux, K-VIROGREF Study Group*, Eric Durot
Format: Article
Language:English
Published: Wiley 2023-02-01
Series:HemaSphere
Online Access:http://journals.lww.com/10.1097/HS9.0000000000000833

Internet

http://journals.lww.com/10.1097/HS9.0000000000000833

Similar Items